30-day FRN

Federal Register / Vol. 84, No. 169 / Friday, August 30, 2019 / Notices
components will continue in them or
their successors pending further
redelegations, provided they are
consistent with this reorganization.

Procedures for Providing Public Input:
Members of the public are encouraged
to go to the NBSB website (http://
www.phe.gov/nbsb) for instructions
about the submission of written
comments.

Authority: 44 U.S.C. 3101.
Scott W. Rowell,
Assistant Secretary for Administration.

Dated: August 21, 2019.
Robert P. Kadlec,
Assistant Secretary for Preparedness and
Response.

[FR Doc. 2019–18784 Filed 8–29–19; 8:45 am]
BILLING CODE 4150–05–P

[FR Doc. 2019–18612 Filed 8–29–19; 8:45 am]

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

BILLING CODE 4150–37–P

National Biodefense Science Board:
Public Meeting

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Office of the Assistant
Secretary for Preparedness and
Response (ASPR), Department of Health
and Human Services (HHS).
ACTION: Notice.

National Institutes of Health

AGENCY:

The HHS Office of the
Secretary is hosting the National
Biodefense Science Board (NBSB)
Public Meeting in Washington, DC, on
September 11, 2019. The purpose of the
meeting is to gather information to
develop expert advice provided by
NBSB and guidance to the Secretary on
scientific, technical, and other matters
of special interest to HHS regarding
current and future chemical, biological,
nuclear, and radiological agents,
whether naturally occurring, accidental,
or deliberate.
DATES: The NBSB Public Meeting is
being held on September 11, 2019, from
9:00 a.m. to 5:00 p.m. Eastern Daylight
Time (EDT).
ADDRESSES: Please visit the NBSB
website (https://www.phe.gov/nbsb) for
all additional information regarding
NBSB or meeting details.
FOR FURTHER INFORMATION CONTACT:
CAPT Christopher Perdue, MD, MPH,
Designated Federal Official, NBSB,
ASPR, HHS; 202–401–5837;
christopher.perdue@hhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to section 319M of the Public Health
Service Act, HHS has established the
NBSB to provide expert advice and
guidance to the Secretary on scientific,
technical, and other matters of special
interest to HHS regarding current and
future chemical, biological, nuclear, and
radiological agents, whether naturally
occurring, accidental, or deliberate.
Availability of Materials: Participants
are encouraged to visit the NBSB
website (http://www.phe.gov/nbsb) for
information about the meeting,
including the agenda.

jspears on DSK3GMQ082PROD with NOTICES

SUMMARY:

VerDate Sep<11>2014

16:43 Aug 29, 2019

Jkt 247001

Proposed Collection; 30 Day Comment
Request; The Impact of Clinical
Research Training and Medical
Education at the Clinical Center on
Physician Careers in Academia and
Clinical Research (Clinical Center)
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30 days of the date of this
publication.
SUMMARY:

Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, should be
directed to the: Office of Management
and Budget, Office of Regulatory Affairs,
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974, Attention: Desk
Officer for NIH.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, contact: Robert
M. Lembo, MD, Office of Clinical
Research Training and Medical
Education, NIH Clinical Center,
National Institutes of Health, 10 Center
Drive, Room 1N252C, Bethesda, MD
20892–1158, or call non-toll-free
number (301) 496–2636, or Email your
request, including your address to:
robert.lembo@nih.gov.
ADDRESSES:

PO 00000

Frm 00073

Fmt 4703

Sfmt 4703

45781

This
proposed information collection was
previously published in the Federal
Register on June 12, page 27336 (84 FR
27336) and allowed 60 days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment.
The Clinical Center, National
Institutes of Health, may not conduct or
sponsor, and the respondent is not
required to respond to, an information
collection that has been extended,
revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection Title: The Impact
of Clinical Research Training and
Medical Education at the Clinical Center
on Physician Careers in Academia and
Clinical Research, OMB #0925–0602
Expiration Date: 8/31/19, Revision,
Clinical Center (CC), National Institutes
of Health (NIH).
Need and Use of Information
Collection: The information collected
will allow continued assessment of the
value of the training provided by the
Office of Clinical Research Training and
Medical Education (OCRTME) at the
NIH Clinical Center and the extent to
which this training promotes (a) patient
safety; (b) research productivity and
independence; and (c) future career
development within clinical,
translational, and academic research
settings. The information received from
respondents is presented to, evaluated
by, and incorporated into the ongoing
operational improvement efforts of the
Director of the Office of Clinical
Research Training and Education, and
the Chief Executive Officer of the NIH
Clinical Center. This information will
enable the ongoing operational
improvement efforts of the OCRTME
and its commitment to providing
clinical research training and medical
education of the highest quality to each
trainee.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours 478.

SUPPLEMENTARY INFORMATION:

E:\FR\FM\30AUN1.SGM

30AUN1

45782

Federal Register / Vol. 84, No. 169 / Friday, August 30, 2019 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent

Average
burden per
response
(in hours)

Total annual
burden hours
requested

Type of respondents

CRTP/MRSP Alumni Survey ................................
Summer Internship Program Alumni Survey ........
Graduate Medical Education Graduate Survey ....
Clinical Electives Program 1 Year Alumni Surveys.

Post Doctoral Students
Pre Doctoral Students ..
Physicians ....................
Physicians ....................

704
280
350
100

1
1
1
1

20/60
20/60
20/60
20/60

235
93
117
33

Total ...............................................................

.......................................

........................

1,434

........................

478

Dated: August 20, 2019.
Laura M. Lee,
Project Clearance Liaison, NIH Clinical
Center, National Institutes of Health.
[FR Doc. 2019–18840 Filed 8–29–19; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice
AGENCY:

The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at http://www.samhsa.gov/
workplace.

SUMMARY:

jspears on DSK3GMQ082PROD with NOTICES

Number of
respondents

Form name

FOR FURTHER INFORMATION CONTACT:

Charles LoDico, Division of Workplace
Programs, SAMHSA/CSAP, 5600

VerDate Sep<11>2014

16:43 Aug 29, 2019

Jkt 247001

Fishers Lane, Room 16N02C, Rockville,
Maryland 20857; 240–276–2600 (voice).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITF) currently
certified to meet the standards of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory
Guidelines were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
specimen validity tests on urine
specimens for federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated January 23, 2017 (82
FR 7920), the following HHS-certified
laboratories and IITFs meet the
minimum standards to conduct drug

PO 00000

Frm 00074

Fmt 4703

Sfmt 4703

and specimen validity tests on urine
specimens:
HHS-Certified Instrumented Initial
Testing Facilities
Dynacare, 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7, 780–
784–1190, (Formerly: GammaDynacare Medical Laboratories).
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
844–486–9226.
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.).
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.).
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center).
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917.
Cordant Health Solutions, 2617 East L
Street, Tacoma, WA 98421, 800–442–
0438, (Formerly: STERLING Reference
Laboratories).
Desert Tox, LLC, 10221 North 32nd
Street Suite J, Phoenix, AZ 85028,
602–457–5411.
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890.
Dynacare, * 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
* The Standards Council of Canada (SCC) voted
to end its Laboratory Accreditation Program for
Substance Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that program were
accredited to conduct forensic urine drug testing as
required by U.S. Department of Transportation
(DOT) regulations. As of that date, the certification
of those accredited Canadian laboratories will
continue under DOT authority. The responsibility

E:\FR\FM\30AUN1.SGM

30AUN1